fda approves first oral glp-1 obesity drug august 21 2025 Wegovy Pill Wins Approval as Treatment for and Weight Loss Drugmakers are racing to find
Description
Gearhardt et al., 2011
Dulaglutide and insulin microsecretion in people with type 1 diabetes (DIAMOND-GLP-1): A randomized double-blind placebo-controlled trial
However, the story did not end there
Semaglutide 2.4 mg significantly decreased total body weight loss in individuals with obesity by 16.1% as opposed to 0.6% with a placebo
As well as physical health risks, the stigma attached to excess body weight and obesity can have adverse psychosocial consequences and lower the quality of life
Ma C, Avenell A, Bolland M, Hudson J, Stewart F, Robertson C, et al
